Akums Drugs & Pharmaceuticals' Q4 FY 2025-26 Quarterly Results

Result Summary

• Akums Drugs & Pharmaceuticals Ltd reported a 0.1% quarter-on-quarter (QoQ) decrease in its consolidated revenues for the quarter-ended Mar (Q4 FY 2025-26). On a year-on-year (YoY) basis, it witnessed a growth of 11.2%.
• Its expenses for the quarter were down by 0.6% QoQ and up 6.4% YoY.
• The net profit increased 20.2% QoQ and decreased 45.6% YoY.
• The earnings per share (EPS) of Akums Drugs & Pharmaceuticals Ltd stood at 5.53 during Q4 FY 2025-26.

Financial Statments for Q4 FY 2025-26

Data Source: BSE, Company announcements The securities quoted are exemplary and are not recommendatory. Past performance is not indicative of future results

## Company Overview
Akums Drugs & Pharmaceuticals Ltd is a prominent player in the pharmaceutical industry, primarily engaged in the manufacturing and marketing of pharmaceutical formulations. The company has established itself as a significant contract manufacturing organization, offering a wide range of products including tablets, capsules, syrups, and more. Akums is known for its high-quality production standards and compliance with international manufacturing practices. As of now, there is no specific information available regarding recent major developments or strategic changes within the company.

## Revenue
During the fourth quarter of fiscal year 2026 (Q4FY26), Akums Drugs & Pharmaceuticals Ltd reported a total income of ₹1193.17 crores. This figure shows a marginal decline of 0.1% compared to the previous quarter (Q3FY26), where the total income was ₹1193.92 crores. On a year-over-year basis, the company achieved an 11.2% increase in total income from Q4FY25, which recorded a total income of ₹1073.09 crores. Despite minor fluctuations on a quarterly basis, the company has demonstrated significant growth in its revenue over the past year.

## Profitability
In Q4FY26, Akums Drugs & Pharmaceuticals Ltd saw a profit before tax amounting to ₹121.22 crores, marking a substantial 21.7% increase from the preceding quarter's ₹99.57 crores. When compared to the same period last year (Q4FY25), there is an impressive 61.3% increase from ₹75.14 crores. The tax expense for Q4FY26 was ₹39.87 crores, which represents a 25.0% increase from the previous quarter. The profit after tax in Q4FY26 stood at ₹81.34 crores, reflecting a 20.2% rise from the prior quarter but a 45.6% decrease from Q4FY25's ₹149.61 crores. Earnings per share (EPS) in Q4FY26 was ₹5.53, which increased by 27.7% from the previous quarter but decreased by 42.6% year-over-year from ₹9.64.

## Operating Metrics
The total expenses for Akums Drugs & Pharmaceuticals Ltd in Q4FY26 were ₹1070.16 crores. This represents a slight decline of 0.6% from Q3FY26, where total expenses were ₹1076.12 crores. Compared to the same quarter in the previous year, there is an increase of 6.4% from ₹1006.17 crores. The changes in expenses, alongside income fluctuations, have influenced the company's profitability and earnings per share. The reported financial data does not include specific metrics such as the P/E ratio, debt-to-equity ratio, or current ratio, thus these were not calculated. This section focuses on the operational costs and their impact on financial outcomes for the quarter.